NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · OPCH · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Option Care Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Option Care Health, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $0.49. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Option Care Health, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses. They also provide immunoglobulin infusions for immune system deficiencies and treatments targeting chronic inflammatory disorders like Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Furthermore, Option Care Health assists in managing the progression of neurological conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy. They also administer infusion therapies for bleeding disorders and provide crucial support for women experiencing high-risk pregnancies. Other specialized infusion services encompass pain relief, chemotherapy, and respiratory care. Complementing these medical offerings, the company provides professional nursing services. Option Care Health, Inc. maintains its primary corporate office in Bannockburn, Illinois.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 29, 2025 | $0.40+11.11% vs estimate | $1.33B-0.24% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | $0.35+6.06% vs estimate | $1.35B+9.49% vs estimate |
|---|
| Q3 2024 | Oct 30, 2024 | $0.310.0% vs estimate | $1.28B+0.71% vs estimate |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 7 contributors · Median target $32.03.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$131.49+$9.41 (+7.7%)
Encompass Health Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.69% below the high.
$186.32+$2.21 (+1.2%)
The Ensign Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.53% below the high.
$541.92+$8.56 (+1.6%)
Chemed Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
$13.26+$0.20 (+1.53%)
Aveanna Healthcare Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.86% below the high.
$42.48+$0.32 (+0.76%)
The Pennant Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.14% below the high.
